Biotron Ltd (BIT) - Total Liabilities
Based on the latest financial reports, Biotron Ltd (BIT) has total liabilities worth AU$1.16 Million AUD (≈ $821.73K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotron Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Biotron Ltd's total liabilities have evolved over time, based on quarterly financial data. See BIT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Biotron Ltd Competitors by Total Liabilities
The table below lists competitors of Biotron Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
St-Georges Eco-Mining Corp
F:85G1
|
Germany | €6.87 Million |
|
Akshar Spintex Limited
NSE:AKSHAR
|
India | Rs112.15 Million |
|
BPH Energy Ltd
AU:BPH
|
Australia | AU$786.23K |
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
USA | $2.85 Million |
|
Knosys Ltd
AU:KNO
|
Australia | AU$7.55 Million |
|
Shamaym Improve Ltd
TA:SHMM
|
Israel | ILA803.40K |
|
BlackRock Frontiers Investment Trust plc
LSE:BRFI
|
UK | GBX14.41 Million |
|
Chijet Motor Company, Inc. Ordinary Shares
NASDAQ:CJET
|
USA | $657.20 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Biotron Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biotron Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotron Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotron Ltd (2000–2025)
The table below shows the annual total liabilities of Biotron Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$428.51K ≈ $303.20K |
-41.90% |
| 2024-06-30 | AU$737.51K ≈ $521.83K |
-23.38% |
| 2023-06-30 | AU$962.49K ≈ $681.03K |
+18.31% |
| 2022-06-30 | AU$813.57K ≈ $575.65K |
+75.52% |
| 2021-06-30 | AU$463.51K ≈ $327.96K |
-45.67% |
| 2020-06-30 | AU$853.19K ≈ $603.69K |
+104.11% |
| 2019-06-30 | AU$418.00K ≈ $295.76K |
+23.78% |
| 2018-06-30 | AU$337.70K ≈ $238.95K |
-45.49% |
| 2017-06-30 | AU$619.51K ≈ $438.34K |
+78.89% |
| 2016-06-30 | AU$346.32K ≈ $245.04K |
-26.81% |
| 2015-06-30 | AU$473.18K ≈ $334.80K |
-0.31% |
| 2014-06-30 | AU$474.64K ≈ $335.84K |
+21.37% |
| 2013-06-30 | AU$391.08K ≈ $276.71K |
+103.50% |
| 2012-06-30 | AU$192.18K ≈ $135.98K |
-21.34% |
| 2011-06-30 | AU$244.32K ≈ $172.87K |
+74.16% |
| 2010-06-30 | AU$140.29K ≈ $99.26K |
-36.90% |
| 2009-06-30 | AU$222.33K ≈ $157.31K |
-47.56% |
| 2008-06-30 | AU$423.94K ≈ $299.97K |
+160.05% |
| 2007-06-30 | AU$163.02K ≈ $115.35K |
-48.75% |
| 2006-06-30 | AU$318.11K ≈ $225.08K |
+112.24% |
| 2005-06-30 | AU$149.88K ≈ $106.05K |
-2.25% |
| 2004-06-30 | AU$153.33K ≈ $108.49K |
+3.55% |
| 2003-06-30 | AU$148.08K ≈ $104.77K |
+3.63% |
| 2002-06-30 | AU$142.90K ≈ $101.11K |
+28.22% |
| 2001-06-30 | AU$111.45K ≈ $78.86K |
+406.59% |
| 2000-06-30 | AU$22.00K ≈ $15.57K |
-- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.